Condition

Chronic Lymphocytic Leukemia clinical trials and research

• 94Clinical trials
• 27NIH research projects
• 48Countries

Newest Chronic Lymphocytic Leukemia clinical trials

All recruiting trials (94)

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Nemtabrutinib and venetoclax in untreated CLL/SLL

  This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07557056

• NX-5948 plus other medicines for B-cell cancers

  This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.

  Recruiting at 5 sites Phase 1/2 Nurix Therapeutics, Inc. · Aurora, Colorado and 8 other locations · NCT07520006

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• Adding a targeted cancer drug to standard therapy for untreated CLL/SLL

  This trial tests whether adding sonrotoclax to zanubrutinib helps people with untreated CLL/SLL live longer without the disease getting worse.

  Recruiting at 259 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 260 other locations · NCT07321652

• Acalabrutinib for CLL in routine care in Belarus

  This project will see how well acalabrutinib works and how safe it is for adults with chronic lymphocytic leukemia treated in routine clinical practice in Belarus.

  Recruiting at 3 sites AstraZeneca · Grodno and 3 other locations · NCT07288515

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Emavusertib plus zanubrutinib for CLL and other B‑cell cancers

  This test will see if adding emavusertib to the BTK inhibitor zanubrutinib can reduce measurable residual disease in adults with chronic lymphocytic leukemia or other B‑cell malignancies.

  Recruiting at 11 sites Phase 2 Curis, Inc. · Miami Beach, Florida and 10 other locations · NCT07271667

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

• Long-term pirtobrutinib treatment for people with previously treated CLL/SLL

  This trial will test whether taking pirtobrutinib long-term is safe for people who have already been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  Recruiting at 22 sites Phase 4 Eli Lilly and Company · Mobile, Alabama and 49 other locations · NCT07218341

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Why some people with chronic lymphocytic leukemia respond to BTK degrader drugs

  This project collects blood, bone marrow, or leftover lymph node samples from adults with CLL who are candidates for or have received BTK degrader drugs to see why some people respond and others become resistant.

  Recruiting at 2 sites Nantes University Hospital · Angers and 13 other locations · NCT07099443

• Mosunetuzumab to clear minimal residual disease in CLL and SLL.

  This trial will try mosunetuzumab, alone or with a BTK inhibitor, to clear minimal residual disease in people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07052695

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Intermittent versus continuous venetoclax with acalabrutinib in CLL/SLL

  This will test whether giving venetoclax intermittently or continuously together with acalabrutinib helps people with previously untreated CLL or SLL.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07014917

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• Comparing a BTK-targeted protein degrader (BGB-16673) with pirtobrutinib for adults with relapsed or refractory CLL or SLL

  This trial tests whether BGB-16673 works better and is as safe as pirtobrutinib for adults whose CLL or SLL has come back or not responded after prior covalent BTK inhibitor treatment.

  Recruiting at 217 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 216 other locations · NCT06973187

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Time-limited combination of pirtobrutinib, venetoclax and obinutuzumab for relapsed CLL/SLL

  This trial will test whether a time-limited combination of pirtobrutinib, venetoclax, and obinutuzumab can control relapsed CLL/SLL in adults who have had prior therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06967610

• Comparing sonrotoclax combinations versus venetoclax plus rituximab for relapsed or refractory CLL/SLL

  This trial will test whether sonrotoclax combined with obinutuzumab or with rituximab works better than venetoclax plus rituximab for adults whose CLL/SLL has come back or not responded to prior treatment.

  Recruiting at 181 sites Phase 3 BeOne Medicines · Laguna Hills, California and 194 other locations · NCT06943872

• Long-term pirtobrutinib continuation for people with previously treated CLL/SLL or non-Hodgkin lymphoma

  People who are already taking pirtobrutinib in an earlier trial can continue the drug or their follow-up visits so doctors can see if it stays safe and keeps helping over the long term.

  Recruiting at 25 sites Phase 4 Eli Lilly and Company · Miami, Florida and 35 other locations · NCT06876662

• Long-term safety follow-up of pirtobrutinib for chronic lymphocytic leukemia and non-Hodgkin lymphoma

  This program lets people who previously received pirtobrutinib in a Lilly study continue treatment or follow-up so doctors can see if the drug remains safe over the long term.

  Recruiting at 32 sites Phase 4 Eli Lilly and Company · Jacksonville, Florida and 37 other locations · NCT06876649

• Nemtabrutinib plus pembrolizumab for Richter transformation (DLBCL subtype)

  This phase II trial tests whether combining nemtabrutinib and pembrolizumab can shrink tumors and help people whose chronic lymphocytic leukemia has transformed into diffuse large B‑cell lymphoma (Richter transformation).

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06863402

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Zanubrutinib, obinutuzumab, and sonrotoclax for newly diagnosed CLL or SLL

  This trial tests whether the three‑drug combination of zanubrutinib, obinutuzumab, and sonrotoclax can produce undetectable measurable residual disease (uMRD) in people with previously untreated CLL or SLL.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06849713

• Comparing BGB-16673 to standard treatments for chronic lymphocytic leukemia

  This study is testing a new treatment called BGB-16673 to see if it works better than standard options for people with chronic lymphocytic leukemia who have already tried other therapies.

  Recruiting at 132 sites Phase 3 BeOne Medicines · Jonesboro, Arkansas and 131 other locations · NCT06846671

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Treatment of Chronic Lymphocytic Leukaemia with Pirtobrutinib after Zanubrutinib

  This study is testing if the drug pirtobrutinib can help people with chronic lymphocytic leukaemia who didn’t respond to or relapsed after treatment with zanubrutinib.

  Recruiting Phase 2 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria and 2 other locations · NCT06812715

• Long-term survival after different first-line treatments for CLL

  This follow-up will see if people with CLL who received different first-line treatments in GCLLSG trials live longer over time.

  Recruiting at 2 sites German CLL Study Group · Cologne and 1 other locations · NCT06792994

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Investigating a new dosing schedule for sonrotoclax in blood cancer treatment

  This study is testing new ways to give the drug sonrotoclax to see if it can safely help people with chronic lymphocytic leukemia (CLL) feel better.

  Recruiting at 22 sites Phase 1/2 BeOne Medicines · Tampa, Florida and 21 other locations · NCT06697184

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Evaluating Pirtobrutinib for patients with relapsed or refractory CLL/SLL

  This study is testing a new medication called Pirtobrutinib to see if it helps people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma feel better after they’ve already tried other treatments.

  Recruiting at 125 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 128 other locations · NCT06588478

• Quality of life for people with CLL treated with acalabrutinib in France (PLATON database retrospective analysis)

  This project will test how quality of life changes during the first 12 months in adults with CLL who start acalabrutinib in real-world care in France.

  Recruiting AstraZeneca · Saint-Affrique · NCT06548152

• Combining zanubrutinib and obinutuzumab for untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing if combining two medications, zanubrutinib and obinutuzumab, can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve better treatment results.

  Recruiting at 19 sites Phase 2 PETHEMA Foundation · Alicante and 18 other locations · NCT06544785

• Evaluating bone marrow function in patients with CLL and MBL compared to healthy individuals

  This study is trying to see how bone marrow function is different in people with Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL) compared to healthy individuals.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06536452

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Continuing a BTK inhibitor alone versus adding venetoclax for veterans with CLL/SLL

  This will try adding venetoclax for one year to a BTKi in veterans with CLL or SLL who are already responding, to see if they can stop therapy safely compared with staying on BTKi alone.

  Recruiting at 4 sites Phase 2 VA Office of Research and Development · San Francisco, California and 3 other locations · NCT06520098

• Understanding immune deficiency in untreated Chronic Lymphocytic Leukemia patients

  This study looks at how untreated Chronic Lymphocytic Leukemia affects the immune system and tries to find out why these patients are more likely to get infections.

  Recruiting CHU de Reims · Reims · NCT06475469

• Combining pirtobrutinib and venetoclax for treating resistant CLL or SLL

  This study is testing if combining two drugs, pirtobrutinib and venetoclax, can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that hasn’t responded to previous treatments.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06466122

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Using Wisconsin ginseng to reduce cancer-related fatigue

  This study is testing if Wisconsin ginseng can help reduce fatigue in cancer patients compared to a placebo over eight weeks.

  Recruiting at 14 sites Phase 3 Mayo Clinic · Albert Lea, Minnesota and 14 other locations · NCT06395441

• Fixed-duration treatment for chronic lymphocytic leukemia with pirtobrutinib and obinutuzumab

  This study is testing a year-long treatment combining two medications, pirtobrutinib and obinutuzumab, to see if it helps people with chronic lymphocytic leukemia feel better.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT06333262

• Seeing CXCR4 in lymphoma and leukemia with a new PET tracer

  This study tests a new PET tracer called 18F-BL40 to see if it can image CXCR4-expressing cancers and compares it with the standard 18F-FDG in adults with various blood cancers.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06224309

• Evaluating blood pressure management in patients with B-cell cancers on specific treatments

  This study is trying to see how blood pressure changes in people with B-cell cancers who are being treated with a specific type of medication, and what the best ways are to manage any high blood pressure they might develop.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151730

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

• Vaccination to prevent CMV infection in stem cell transplant patients

  This study is testing a new vaccine to see if it can help prevent CMV infections in patients receiving stem cell transplants from related donors.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06059391

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Safety evaluation of CC312 in adults with relapsed B-cell cancers

  This study is testing a new treatment called CC312 to see if it's safe for adults with relapsed B-cell cancers.

  Recruiting Phase 1 CytoCares Inc · Tianjin, Tianjin Municipality · NCT06037018

• Acalabrutinib in first-line CLL in Spain: real-world observation

  This study looks at how patients with chronic lymphocytic leukemia do when they start acalabrutinib as their first CLL treatment in Spain, using real-world data from multiple centers.

  Recruiting at 15 sites AstraZeneca · Almería, Andalusia and 49 other locations · NCT05999877

• Combination treatment for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT05943496

• Metabolically enhanced CAR T-cell therapy for relapsed B-cell cancers

  This study is testing a new way to improve CAR T-cell therapy for patients with relapsed B-cell cancers to see if it can work better and be safer.

  Recruiting Phase 1/2 Medical University of South Carolina · Charleston, South Carolina · NCT05702853

• Using ibrutinib to treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia

  This study is testing if the drug ibrutinib can help adults with chronic lymphocytic leukemia who also have autoimmune hemolytic anemia feel better.

  Recruiting at 3 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence and 2 other locations · NCT05694312

• Monitoring heart rhythms in patients starting BTK inhibitors

  This study is testing how well a heart monitor can detect new heart rhythm problems in patients starting treatment with BTK inhibitors.

  Recruiting Northwell Health · New Hyde Park, New York · NCT05643235

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Vaccination strategy for patients with chronic lymphocytic leukemia

  This study is testing a new vaccination schedule to see if it helps people with chronic lymphocytic leukemia better fight off infections compared to the usual vaccination plan.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05417165

• Comparing early and delayed therapy for high-risk patients with chronic lymphocytic leukemia.

  This study is trying to see if starting treatment right away or waiting longer is better for high-risk patients with chronic lymphocytic leukemia and how it affects their healthcare costs.

  Recruiting at 4 sites Canadian Cancer Trials Group · Vancouver, British Columbia and 5 other locations · NCT05371808

• Acalabrutinib combined with venetoclax or obinutuzumab for treating chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, acalabrutinib with either venetoclax or obinutuzumab, can help people with chronic lymphocytic leukemia who haven't been treated before by reducing cancer cells in their bone marrow.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05336812

• Collecting blood samples to evaluate tests for early cancer detection

  This study is collecting blood and tissue samples from people with and without cancer to see if new tests can help detect cancer earlier.

  Recruiting at 619 sites Alliance for Clinical Trials in Oncology · Anchorage, Alaska and 750 other locations · NCT05334069

• Evaluating zanubrutinib treatment in patients with certain blood cancers

  This study is trying to see how well zanubrutinib works and how it affects the lives of adults with certain blood cancers like Waldenström's Macroglobulinemia and Chronic Lymphocytic Leukemia.

  Recruiting at 2 sites iOMEDICO AG · Salzburg and 1 other locations · NCT05326308

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Pirtobrutinib versus ibrutinib for people with CLL or SLL.

  This trial will test whether pirtobrutinib works better or is safer than ibrutinib for adults with CLL/SLL, with a separate part that tries pirtobrutinib alone in treatment‑naïve patients who have a 17p deletion.

  Recruiting at 93 sites Phase 3 Eli Lilly and Company · Anaheim, California and 142 other locations · NCT05254743

• Understanding resistance to venetoclax in chronic lymphocytic leukemia

  This study is trying to understand why some patients with chronic lymphocytic leukemia don’t respond to the treatment venetoclax by looking at their medical information and samples.

  Recruiting University Hospital, Clermont-Ferrand · Amiens and 13 other locations · NCT05246345

• Combination treatment for high-risk chronic lymphocytic leukemia

  This study is testing if a new combination of three drugs can help people with high-risk chronic lymphocytic leukemia live longer without their cancer getting worse compared to a combination of two drugs.

  Recruiting at 30 sites Phase 3 German CLL Study Group · Bad Saarow and 29 other locations · NCT05197192

• Vaccination for Pneumonia in Patients with Chronic Lymphocytic Leukemia

  This study tests if a pneumonia vaccine can help boost the immune response in people with chronic lymphocytic leukemia and reduce their chances of getting pneumonia.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT05183854

• APG-2575 treatment for patients with relapsed or refractory CLL/SLL

  This study is testing a new oral medication called APG-2575 to see if it can help people with relapsed or hard-to-treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

  Recruiting at 4 sites Phase 2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 10 other locations · NCT05147467

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Fecal Microbiota Transplantation to Prevent Complications After Stem Cell Transplantation

  This study is testing whether giving a special stool treatment can help prevent complications like Graft-versus-Host Disease in patients receiving stem cell transplants for blood cancers.

  Recruiting at 3 sites Phase 2 University Hospital, Clermont-Ferrand · Amiens and 19 other locations · NCT04935684

• Fixed-duration treatment for chronic lymphocytic leukemia with ibrutinib and obinutuzumab

  This study is testing a new treatment plan using ibrutinib and obinutuzumab for people with chronic lymphocytic leukemia who haven't been treated before, to see if it can help them reach a point where the disease is undetectable in their bone marrow.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, MI · NCT04908228

• Collecting data on Chronic Lymphocytic Leukemia in Italy

  This study is collecting information from patients newly diagnosed with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B-Cell Lymphocytosis in Italy to better understand these conditions.

  Recruiting at 24 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · Alessandria and 23 other locations · NCT04867915

• Effects of Nicotinamide on Chronic Lymphocytic Leukemia Patients with Skin Cancer History

  This study is testing if taking nicotinamide can help prevent new skin cancers in people with chronic lymphocytic leukemia who have a history of skin cancer.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT04844528

• Metabolic profiling in chronic lymphocytic leukemia

  This study is trying to understand how cancer cells in people with chronic lymphocytic leukemia use different fuels to see if it can help find new ways to treat the disease.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT04785989

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Intermittent dosing of ibrutinib for advanced chronic lymphocytic leukemia

  This study is testing if taking the cancer drug ibrutinib in a 'ON-OFF' way can help people with advanced chronic lymphocytic leukemia stay healthy while possibly having fewer side effects and lower costs.

  Recruiting at 6 sites Phase 1/2 Karolinska University Hospital · Trondheim and 8 other locations · NCT04771507

• KRT-232 plus acalabrutinib in relapsed/refractory DLBCL or CLL

  This trial tests a new MDM2 inhibitor (KRT-232) together with acalabrutinib to see if the combination helps adults with relapsed or refractory DLBCL or CLL.

  Recruiting at 45 sites Phase 1/2 Kartos Therapeutics, Inc. · Goshen, Indiana and 44 other locations · NCT04502394

• APG-2575 treatment for relapsed/refractory CLL/SLL

  This study is testing a new treatment called APG-2575, both alone and with other medications, to see how well it works for people with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

  Recruiting at 17 sites Phase 1/2 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 17 other locations · NCT04494503

• Early treatment for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study tests if starting treatment early with venetoclax and obinutuzumab can help people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma live longer and feel better compared to waiting until symptoms show up.

  Recruiting at 299 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 632 other locations · NCT04269902

• Understanding Chronic Lymphocytic Leukemia

  This study is collecting tissue samples and medical information from people with Chronic Lymphocytic Leukemia to see what causes the disease and find better treatments.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04028531

• Investigating how venetoclax affects chronic lymphocytic leukemia

  This study is testing how the medication venetoclax affects people with chronic lymphocytic leukemia during the early stages of treatment to see how it impacts their cancer and overall health.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03986034

• Evaluating a new treatment approach for chronic lymphocytic leukemia

  This study is testing a new treatment plan that combines two established therapies with ibrutinib to see if it helps people with chronic lymphocytic leukemia who haven't had treatment before.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT03980002

• CLIC-1901 treatment for relapsed/refractory CD19 positive blood cancers

  This study is testing a new treatment called CLIC-1901 for people with hard-to-treat blood cancers to see if it can help them feel better.

  Recruiting at 2 sites Phase 1/2 Ottawa Hospital Research Institute · Vancouver, British Columbia and 2 other locations · NCT03765177

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• Evaluating the safety of azer-cel in patients with relapsed/refractory B-cell cancers

  This study is testing a new treatment called azer-cel to see if it is safe and effective for adults with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 15 sites Phase 1 Imugene Limited · Tampa, Florida and 14 other locations · NCT03666000

• Acalabrutinib with or without Obinutuzumab for early-stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  This study is testing whether a new drug called acalabrutinib, alone or with another drug called obinutuzumab, can help people with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT03516617

• Evaluating immune responses to influenza vaccination in lymphoma patients

  This study is testing how well the flu vaccine works for people with lymphoma by checking their immune responses after getting vaccinated.

  Recruiting at 2 sites Emory University · Atlanta, Georgia and 1 other locations · NCT03501576

• Long-term follow-up of patients receiving CAR-T cell therapy

  This study is tracking patients who have received CAR-T cell therapy for up to 15 years to see how well the treatment works over time and if there are any long-term health issues.

  Recruiting Medical College of Wisconsin · Milwaukee, Wisconsin · NCT03375619

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Collecting and reporting data on patients receiving stem cell transplants

  This study is trying to gather and share information about patients getting stem cell transplants for blood cancers to better understand how well these treatments work.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT01890486

• Using modified T-cells to treat advanced B-cell cancers

  This study is testing whether modified T-cells can help patients with advanced B-cell cancers that haven't responded to other treatments by boosting their immune system to fight the cancer better.

  Recruiting at 2 sites Phase 1 Baylor College of Medicine · Houston, Texas and 1 other locations · NCT01853631

NIH-funded research (27)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome

  A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11391354

• Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults

  A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11383115

• AVO: a new triplet therapy for untreated high-risk CLL

  A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11382050

• Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia

  A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.

  NIH research Stanford University · Stanford, United States · NIH-11367607

• METTL3's role in driving a stubborn form of chronic lymphocytic leukemia

  A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11364209

• Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia

  Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11355604

• National teamwork to improve care for chronic lymphocytic leukemia and B‑cell lymphomas

  This effort brings together national cancer groups to test new targeted and combination treatments for adults with chronic lymphocytic leukemia (CLL) and other B‑cell lymphomas.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11294169

• Personalized tumor targets to help the immune system fight CLL

  Researchers are developing personalized tumor markers to help the immune systems of people with chronic lymphocytic leukemia (CLL) recognize and attack their cancer.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11285204

• Reducing harmful cell stress in chronic lymphocytic leukemia (CLL)

  This project tests blocking a specific cell 'stress' pathway to slow aggressive B‑cell chronic lymphocytic leukemia in people with CLL.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11262307

• Why some early B‑cell changes progress to chronic lymphocytic leukemia (CLL)

  This work looks at inherited gene variants and chemical tags on DNA to find which people with monoclonal B‑cell lymphocytosis (MBL) are more likely to develop CLL.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11181017

• New first-line treatment combinations for chronic lymphocytic leukemia (CLL)

  This work compares different drug combinations—including ibrutinib, venetoclax, and obinutuzumab—for people with previously untreated CLL, with trials for both younger and older adults.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-11164692

• Three‑drug targeted treatment for high‑risk CLL with TP53 changes

  Testing a time‑limited three‑drug combination (acalabrutinib, venetoclax, and obinutuzumab) for people with previously untreated, TP53‑aberrant high‑risk chronic lymphocytic leukemia.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11128794

• Improving treatments for chronic lymphocytic leukemia when current medicines stop working

  This research aims to discover why some chronic lymphocytic leukemia patients stop responding to new medications, so we can find better ways to help them.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-11128567

• Understanding METTL3 in Aggressive Chronic Lymphocytic Leukemia

  This research explores how a protein called METTL3 contributes to aggressive forms of chronic lymphocytic leukemia (CLL) to find new ways to help patients.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-11127460

• Investigating genetic factors linked to chronic lymphocytic leukemia (CLL)

  This study is looking at how certain rare genetic changes, especially in the ATM gene, might make some people more likely to develop chronic lymphocytic leukemia (CLL), and it's inviting patients with known ATM gene changes to help us learn more about how these genetics relate to CLL and family cancer history.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11059143

• Identifying markers for personalized treatment in chronic lymphocytic leukemia

  This study is looking for ways to find special markers in people with chronic lymphocytic leukemia (CLL) that can help doctors create more personalized and effective treatments just for you.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11058432

• Collaborating to improve treatment for chronic lymphocytic leukemia and B-cell lymphomas

  This study is looking for ways to improve treatment and care for people with chronic lymphocytic leukemia (CLL) and B-cell lymphomas, and it offers patients a chance to join exciting new clinical trials that could help them respond better to therapy.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11031397

• Investigating how ceramide affects energy production in chronic lymphocytic leukemia cells

  This study is looking at how a fat molecule called ceramide affects the energy production in chronic lymphocytic leukemia (CLL) cells, with the goal of finding new ways to help treat patients by making these cancer cells die off more effectively.

  NIH research University of Virginia · Charlottesville, United States · NIH-10990219

• Investigating why some patients with chronic lymphocytic leukemia resist treatment with BTK inhibitors

  This study is looking into why some people with chronic lymphocytic leukemia (CLL) don’t respond to certain medications called BTK inhibitors, with the goal of finding better treatment options for those who struggle with these therapies.

  NIH research University of Miami School of Medicine · Coral Gables, United States · NIH-10943869

• New treatments for patients with chronic lymphocytic leukemia

  This study is looking for newly diagnosed patients with chronic lymphocytic leukemia (CLL) to try out new combinations of treatments, like Venetoclax and Ibrutinib, to see how well they work, so you can get access to the latest therapies and help improve care for others in the future.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10942547

• Investigating the genetic factors that lead to chronic lymphocytic leukemia from its precursor state.

  This study is looking at how certain genes might help us understand why some people with a condition called monoclonal B-cell lymphocytosis (MBL) might develop chronic lymphocytic leukemia (CLL) later on, especially focusing on African Americans, so we can find ways to better predict and prevent the disease.

  NIH research Mayo Clinic Rochester · Rochester, United States · NIH-10914019

• Understanding how chronic lymphocytic leukemia changes into Richter's syndrome

  This study is looking at how chronic lymphocytic leukemia (CLL) changes into a more serious condition called Richter's syndrome (RS) to help doctors understand why this happens and find better ways to treat patients like you.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10911251

• Combining new therapies for high-risk chronic lymphocytic leukemia

  This study is testing a new combination of three medicines to see if it can help people with high-risk chronic lymphocytic leukemia (CLL) who haven't started treatment yet, with the goal of making the cancer undetectable and improving their overall health.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-10890036

• Investigating the role of METTL3 in aggressive chronic lymphocytic leukemia

  This study is looking at how a protein called METTL3 affects aggressive chronic lymphocytic leukemia (CLL) and is testing new treatments that could help patients by targeting this protein.

  NIH research Beckman Research Institute/city of Hope · Duarte, United States · NIH-10880367

• Evaluating the addition of Venetoclax for treating chronic lymphocytic leukemia.

  This study is looking at whether adding Venetoclax to the treatment for people with chronic lymphocytic leukemia who are already doing well on another medication can make the treatment work better and cause fewer side effects, all while helping improve your quality of life.

  NIH research Kansas City VA Medical Center · Kansas City, United States · NIH-10801637

• Combining therapies to improve treatment for chronic lymphocytic leukemia

  This study is looking at a new way to treat chronic lymphocytic leukemia (CLL) by using a mix of medicines that target how CLL cells survive, and it’s for patients who want to explore better treatment options.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10767317

• Investigating the role of Th17 cells in chronic lymphocytic leukemia

  This study is looking at how a special type of immune cell called Th17 cells interacts with cancer cells in chronic lymphocytic leukemia (CLL) to find new ways to help improve treatment for patients like you.

  NIH research Feinstein Institute for Medical Research · Manhasset, United States · NIH-10735876

Related topics

Quick answers

How many Chronic Lymphocytic Leukemia clinical trials are recruiting right now?

94, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 48 countries. The most sites are in United States (68 trials), France (19 trials), Australia (16 trials), Italy (16 trials), United Kingdom (14 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 34, Phase 3: 12, Phase 1/2: 12, Phase 1: 9. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →